Lercanidipină Gemax Pharma

Lercanidipine, the active ingredient in Lercanidipine Gemax Pharma, is a dihydropyridine calcium channel blocker presented as a tablet for oral use. It is used to lower elevated blood pressure in adult patients.

GNH USA supplies Lercanidipine Gemax Pharma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is indicated for the management of arterial hypertension, acting on the vascular smooth‑muscle calcium channels to lower blood pressure.

- Essential hypertension: reduces systolic and diastolic blood pressure in adults. - Isolated systolic hypertension: provides effective control of elevated systolic pressure. - Secondary hypertension (renovascular, endocrine): used as part of combination therapy to achieve target pressures.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: warm sensation, often on the face. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness. - Tachycardia: increased heart rate. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Angioedema: swelling of lips, tongue, or airway. - Severe hypotension: marked drop in blood pressure causing syncope. - Myocardial infarction: rare occurrence in susceptible patients. - Hepatic injury: elevated liver enzymes or hepatitis. - Severe allergic reaction: rash, hives, or anaphylaxis.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Hepatic impairment: use with caution; dose adjustment may be required. - Concomitant antihypertensives: assess for additive blood‑pressure lowering effects. - Cardiovascular disease: evaluate for underlying ischemic heart disease. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at below 25°C: keep in the original pack, protect from moisture.

Lercanidipine can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase plasma levels. - Grapefruit juice: may raise drug concentration. - Other calcium‑channel blockers: additive vasodilatory effect leading to hypotension. - Rifampicin or other CYP3A4 inducers: reduce therapeutic effect. - Concurrent use with antihypertensive agents that cause profound hypotension.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance blood‑pressure reduction. - Beta‑blockers: monitor heart rate and blood pressure. - ACE inhibitors or ARBs: watch for excessive blood‑pressure lowering. - NSAIDs: may blunt antihypertensive response. - Lipid‑lowering agents (e.g., statins metabolized by CYP3A4): monitor for increased statin levels.